http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-081875-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6572ff5df928fd17340eb2a8cb6d8502 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4045 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-55 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2018 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-04 |
| filingDate | 2011-06-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0086a97a33f08c414bf1f1c8d4219b24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b0a6c7b551aebdf0ee220cf9e502d21e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d880a1c8571e777e0debb55645a3b5e4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f2c1c6fd402d0d4d06dcd21560a80800 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2e4c03a0b9bfaf2f7e3cab213fb1d29a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_107cb9f92889ee987772309f09df1f49 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1a82d700119605ee95aed5fa0d05fca8 |
| publicationDate | 2012-10-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-081875-A1 |
| titleOfInvention | USE OF THE ASSOCIATION OF A SINUSAL CURRENT INHIBITOR I AND AN INHIBITOR OF THE ANGIOTENSIN CONVERSION ENZYME FOR THE TREATMENT OF CARDIAC INSUFFICIENCY |
| abstract | Use of the association of a selective and specific inhibitor of the sinus current If, more particularly ivabradine or N - {[(7S) -3,4-dimethoxybicyclo [4.2.0] octa-1,3,5-trien- 7-yl] methyl} -3- (7,8-dimethoxy-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl) -N-methyl-3-oxo-1-propanamine and of an angiotensin-converting enzyme inhibitor for the purpose of obtaining medicaments for the treatment of heart failure, more particularly of heart failure with preserved systolic function. Claim 10: Pharmaceutical compositions containing as active ingredients: ivabradine, in hydrochloride form or one of its hydrates or crystalline forms; and perindopril, in the form of tert-butylamine or arginine salt or one of its crystalline hydrates or forms, alone or in combination with one or more pharmaceutically acceptable excipients, for use in the treatment of heart failure. Claim 12: Pharmaceutical compositions containing as active ingredients: N - {[(7S) -3,4-dimethoxycycle [4.2.0] octa-1,3,5-trien-7-yl] methyl} -3- ( 7,8-dimethoxy-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl) -N-methyl-3-oxo-1-propanamine, in the form of hydrochloride or fumarate or of one of its hydrates or crystalline forms; and perindopril, in the form of tert-butylamine or arginine salt or one of its crystalline hydrates or forms, alone or in combination with one or more pharmaceutically acceptable excipients. |
| priorityDate | 2010-06-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 48.